Imagine a world where antibiotics are so precisely targeted that they only attack harmful bacteria, leaving beneficial microorganisms unharmed and reducing the risk of antibiotic resistance. This scenario may not be as far-fetched as it seems, thanks to the pioneering work of researchers at the
A phase 1 clinical trial has brought new hope for patients with B-cell lymphoma, a type of blood cancer, through an innovative cell-based immunotherapy. Researchers from Washington University School of Medicine in St. Louis, along with other collaborators, have explored the safety and potential
The transformative impact of rapid in-house next-generation sequencing (NGS) technology on cancer treatment is becoming increasingly evident. This advancement is particularly significant in enabling personalized medicine and improving patient outcomes. With the progress in molecular testing and the
Gene therapy, a revolutionary approach to treating and preventing diseases by modifying faulty genes, relies heavily on accurate measurement techniques. Ensuring the safety and efficacy of these treatments necessitates precise quantification of adeno-associated virus (AAV) vectors, which deliver
Imagine a world where getting vaccinated no longer means facing a needle and syringe, but instead, involves a simple patch applied to the skin. This prospect is rapidly becoming a reality thanks to the innovative work of the University of Queensland (UQ) and Brisbane-based biotech company Vaxxas.
Glioblastoma multiforme, an aggressive form of brain cancer, has long been a formidable challenge in the medical field. With patient survival rates stagnating around 15 to 18 months, the need for innovative treatment approaches is critical. NeOnc Technologies, under the leadership of Dr. Thomas
